{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:42:40Z","timestamp":1790995360788,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Government and Eli Lilly","award":["ZIA AI001220"],"award-info":[{"award-number":["ZIA AI001220"]}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1136\/ard-2023-225463","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T17:29:15Z","timestamp":1713893355000},"page":"1181-1188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Disease flares with baricitinib dose reductions and development of flare criteria in patients with CANDLE\/PRAAS"],"prefix":"10.1016","volume":"83","clinical-trial-number":[{"clinical-trial-number":"nct01724580","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01724580","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01724580","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1039-3701","authenticated-orcid":false,"given":"Kader","family":"Cetin Gedik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M","family":"Ortega-Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Materne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Rastegar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina A","family":"Montealegre Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6178-6893","authenticated-orcid":false,"given":"Paul A","family":"Brogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yackov","family":"Berkun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Murias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Schalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana A","family":"de Jesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7865-5769","authenticated-orcid":false,"given":"Raphaela","family":"Goldbach-Mansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2023-225463_bib1","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies","volume":"128","author":"Sanchez","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1136\/ard-2023-225463_bib2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s13555-021-00517-9","article-title":"Efficacy and safety of Janus kinase inhibitors in type I interferon-mediated monogenic autoinflammatory disorders: a scoping review","volume":"11","author":"G\u00f3mez-Arias","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1136\/ard-2023-225463_bib3","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/cpt.936","article-title":"Pharmacokinetics, pharmacodynamics, and proposed dosing of the oral JAK1 and JAK2 inhibitor baricitinib in pediatric and young adult CANDLE and SAVI patients","volume":"104","author":"Kim","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1136\/ard-2023-225463_bib4","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1172\/JCI81260","article-title":"Additive loss-of-function proteasome subunit mutations in CANDLE\/PRAAS patients promote type I IFN production","volume":"125","author":"Brehm","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1136\/ard-2023-225463_bib5","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.33368","article-title":"Mutations in proteasome subunit beta type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity","volume":"64","author":"Liu","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-225463_bib6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00281-015-0493-5","article-title":"New monogenic autoinflammatory diseases-a clinical overview","volume":"37","author":"Canna","year":"2015","journal-title":"Semin Immunopathol"},{"key":"10.1136\/ard-2023-225463_bib7","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jaci.2021.10.027","article-title":"Pathogenic insights from genetic causes of autoinflammatory inflammasomopathies and interferonopathies","volume":"149","author":"Lin","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1136\/ard-2023-225463_bib8","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJMoa055137","article-title":"Neonatal-onset multisystem inflammatory disease responsive to interleukin-1Beta inhibition","volume":"355","author":"Goldbach-Mansky","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-225463_bib9","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","article-title":"Use of canakinumab in the cryopyrin-associated periodic syndrome","volume":"360","author":"Lachmann","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-225463_bib10","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1002\/art.23687","article-title":"Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies","volume":"58","author":"Hoffman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-225463_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcz025","article-title":"Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development","volume":"1","author":"Lerner","year":"2019","journal-title":"Brain Commun"},{"key":"10.1136\/ard-2023-225463_bib12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1159\/000506868","article-title":"Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications","volume":"89","author":"Cosci","year":"2020","journal-title":"Psychother Psychosom"},{"key":"10.1136\/ard-2023-225463_bib13","article-title":"Monitoring of BK reactivation and long-term safety on Jak1\/2 inhibition with Baricitinib","volume":"72","author":"Cetin Gedik","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-225463_bib14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/ki.2009.377","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary","volume":"77","author":"Kasiske","year":"2010","journal-title":"Kidney Int"},{"issue":"Suppl 4","key":"10.1136\/ard-2023-225463_bib15","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1111\/j.1600-6143.2009.02904.x","article-title":"BK virus in solid organ transplant recipients","volume":"9","author":"Hirsch","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1136\/ard-2023-225463_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s43586-022-00100-2","article-title":"Designing clinical trials for rare diseases: unique challenges and opportunities","volume":"2","author":"Pizzamiglio","year":"2022","journal-title":"Nat Rev Methods Primers"},{"key":"10.1136\/ard-2023-225463_bib17","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1136\/ard.2011.152728","article-title":"Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes","volume":"70","author":"Kuemmerle-Deschner","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225463_bib18","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.94838","article-title":"Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist","volume":"2","author":"Garg","year":"2017","journal-title":"JCI Insight"},{"key":"10.1136\/ard-2023-225463_bib19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/ard.2010.132613","article-title":"A preliminary score for the assessment of disease activity in hereditary recurrent fevers: results from the AIDAI (auto-inflammatory diseases activity index)","volume":"70","author":"Piram","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225463_bib20","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1136\/annrheumdis-2013-203666","article-title":"Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes","volume":"73","author":"Piram","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225463_bib21","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/annrheumdis-2018-213030","article-title":"Treating juvenile idiopathic arthritis to target: recommendations of an international task force","volume":"77","author":"Ravelli","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225463_bib22","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/art.42087","article-title":"The 2021 European alliance of associations for rheumatology\/American college of rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE\/PRAAS, SAVI, and AGS","volume":"74","author":"Cetin Gedik","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-225463_bib23","unstructured":"Food and Drug Administration. Rare diseases: common issues in drug development guidance for industry. 2019."}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724000098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724000098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2023-225463","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:18:00Z","timestamp":1739521080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724000098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0003496724000098"],"URL":"https:\/\/doi.org\/10.1136\/ard-2023-225463","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease flares with baricitinib dose reductions and development of flare criteria in patients with CANDLE\/PRAAS","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-225463","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 \u00a9 THE AUTHORS. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology, EULAR. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}